Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide in combination with SGLT2i in patients with volume overload and acute heart failure
2024-513799-16-00Phase 4Authorised
- Sponsor
- Ziekenhuis Oost-Limburg
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of acetazolamide, empagliflozin and dapagliflozin in Acute Heart Failure (AHF), sponsored by Ziekenhuis Oost-Limburg. Primary endpoint: 24-hour sodium excretion. Planned start Jan 2025; status: authorised.
02
Drugs
acetazolamideempagliflozindapagliflozin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2024-513799-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513799-16-00.